Receive The Newest Study Notifications

I agree Catabasis Pharmaceuticals Announces Phase 3 PolarisDMD Trial Enrolled Expected Patient Population

by Lance Smith | Dec 17, 2019 | Study Scavenger Clinical Trial Recruitment Platform

— Analysis Shows Patients Enrolled in Phase 2 MoveDMD and Phase 3 PolarisDMD Trials of Edasalonexent in Duchenne Muscular Dystrophy Have Similar Baseline Characteristics — BOSTON–(BUSINESS WIRE)–Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a...

First Patient Enrolls in STEMI DTU Randomized Controlled FDA Trial; Study Aims to Further Demonstrate Impella’s Safety and Effectiveness

by Lance Smith | Dec 17, 2019 | Study Scavenger Clinical Trial Recruitment Platform

DANVERS, Mass.–(BUSINESS WIRE)–Abiomed (NASDAQ: ABMD) announces initiation of the ST-Elevation Myocardial Infarction Door-to-Unloading (STEMI DTU) Pivotal Randomized Controlled Trial (RCT), which will explore whether unloading the heart’s left ventricle...

Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in GEMINI Phase 3 Trial in Major Depressive Disorder

by Lance Smith | Dec 17, 2019 | Study Scavenger Clinical Trial Recruitment Platform

  Demonstrated rapid, durable, and statistically significant improvement in depressive symptoms as measured by MADRS total score compared to placebo (p=0.002 on primary endpoint) Statistically significant improvement at week 1 in MADRS total score compared to...

Cyclo Therapeutics, Inc. to Present Clinical Trial Data on Niemann-Pick type C Disease at the 16th Annual WORLDSymposium

by Lance Smith | Dec 17, 2019 | Study Scavenger Clinical Trial Recruitment Platform

Cyclo Therapeutics, Inc. (OTCQB:CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced its presentation at the WORLDSymposium (“We’re...

BeiGene Announces Results of Phase 3 ASPEN Trial of Zanubrutinib Compared to Ibrutinib for the Treatment of Patients with Waldenström’s Macroglobulinemia

by Lance Smith | Dec 17, 2019 | Study Scavenger Clinical Trial Recruitment Platform

CAMBRIDGE, Mass. and BEIJING, China, Dec. 16, 2019 (GLOBE NEWSWIRE) — BeiGene Co.,Ltd, (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs...

Akero Therapeutics Completes Enrollment in Phase 2a Study in NASH

by Lance Smith | Dec 17, 2019 | Study Scavenger Clinical Trial Recruitment Platform

SAN FRANCISCO, Dec. 16, 2019 /PRNewswire/ — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today...